Related Experiment Video
Updated: Mar 22, 2026
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies
Judy R van Beijnum1, Victor L Thijssen1, Tilman Läppchen2,3
1Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.
Abstract:
Galectins are carbohydrate binding proteins that function in many key cellular processes. We have previously demonstrated that galectins are essential for tumor angiogenesis and their expression is associated with disease progression. Targeting galectins is therefore a potential anti-angiogenic and anti-cancer strategy. Here, we used a rational approach to generate antibodies against a specific member of this conserved protein family, i.e. galectin-1. We characterized two novel mouse monoclonal antibodies that specifically react with galectin-1 in human, mouse and chicken. We demonstrate that these antibodies are excellent tools to study galectin-1 expression and function in a broad array of biological systems. In a potential diagnostic application, radiolabeled antibodies showed specific targeting of galectin-1 positive tumors. In a therapeutic setting, the antibodies inhibited sprouting angiogenesis in vitro and in vivo, underscoring the key function of galectin-1 in this process.
Insights
Researchers developed novel antibodies targeting galectin-1, a protein crucial for tumor growth and blood vessel formation. These antibodies show promise for both diagnosing and treating cancer by inhibiting angiogenesis.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Galectins are carbohydrate-binding proteins involved in critical cellular functions.
- Galectins play a key role in tumor angiogenesis and are linked to disease progression.
- Targeting galectins presents a potential anti-angiogenic and anti-cancer strategy.
Purpose of the Study:
- To generate and characterize novel monoclonal antibodies against galectin-1.
- To evaluate the diagnostic and therapeutic potential of these anti-galectin-1 antibodies.
Main Methods:
- Rational antibody generation against galectin-1.
- Characterization of monoclonal antibodies for cross-species reactivity (human, mouse, chicken).
- In vitro and in vivo assessment of antibody efficacy in inhibiting angiogenesis and targeting tumors.
Main Results:
- Two novel mouse monoclonal antibodies specifically recognizing galectin-1 were developed.
- Antibodies demonstrated utility as tools for studying galectin-1 expression and function.
- Radiolabeled antibodies successfully targeted galectin-1 positive tumors in diagnostic imaging studies.
- Antibodies inhibited sprouting angiogenesis both in vitro and in vivo.
Conclusions:
- Novel antibodies targeting galectin-1 are effective tools for research and diagnostics.
- Anti-galectin-1 antibodies demonstrate therapeutic potential by inhibiting tumor angiogenesis.
- Galectin-1 is a validated target for anti-cancer and anti-angiogenic therapies.
Related Concept Videos
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply
01:24Overview of Cell-Matrix Interactions
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...